Structural and biochemical differences between non-catalytic and catalytic antibodies.

IF 7.3 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
mAbs Pub Date : 2025-12-01 Epub Date: 2025-05-12 DOI:10.1080/19420862.2025.2503978
Taizo Uda, Ryuichi Kato, Yasuteru Shigeta, Shun Hirota, Jun Kobayashi, Hisashi Yoshida, Masato Tsuyuguchi, Kowit Hengphasatporn, Moe Tsujita, Hiroaki Taguchi, Emi Hifumi
{"title":"Structural and biochemical differences between non-catalytic and catalytic antibodies.","authors":"Taizo Uda, Ryuichi Kato, Yasuteru Shigeta, Shun Hirota, Jun Kobayashi, Hisashi Yoshida, Masato Tsuyuguchi, Kowit Hengphasatporn, Moe Tsujita, Hiroaki Taguchi, Emi Hifumi","doi":"10.1080/19420862.2025.2503978","DOIUrl":null,"url":null,"abstract":"<p><p>A conventional antibody can be converted into its catalytic counterparts by deleting Pro95 in the CDR-3 of human and mice antibody light chains, as previously reported. T99wt is a naturally occurring human antibody light chain that we transformed into its catalytic antibody using Pro95 deletion. In peptidase activity tests, T99wt exhibited a low catalytic activity against a synthetic peptide Arg-pNA and hardly cleaved amyloid-β peptide. In contrast, the engineered variant (T99-Pro95(-)) demonstrated significant catalytic activity, effectively cleaving both Arg-pNA substrate and amyloid-β peptides. In this study, the structural basis for the acquisition of enzymatic function through Pro95 deletion in the CDR-3 region of the light chain was elucidated using X-ray crystallography and molecular dynamics (MD) simulations. X-ray crystallography revealed that Pro95 deletion substantially reduces the distance between Asp1 and His93-key residues for catalytic activity - from 9.56 Å in T99wt to 3.84 Å in T99-Pro95(-). The observed decrease in distance indicates a strong interaction between Asp1(Oδ1) and His93(Nε2), contributing to the formation of an active site in T99-Pro95(-). MD simulations revealed that the entire structure exhibits slight fluctuations and adopts various configurations upon the removal of Pro95. In particular, when His residues in the catalytic region are fully deprotonated, Asp1, His93, and Ser27a transiently come into close proximity, enabling the formation of a functional catalytic triad. Catalytic antibodies can be made starting from just the amino acid sequence of a desired mAb, which may be available in databases such as OAS or IMGT. Therefore, our finding represents a significant technological advancement.</p>","PeriodicalId":18206,"journal":{"name":"mAbs","volume":"17 1","pages":"2503978"},"PeriodicalIF":7.3000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077472/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mAbs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19420862.2025.2503978","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

A conventional antibody can be converted into its catalytic counterparts by deleting Pro95 in the CDR-3 of human and mice antibody light chains, as previously reported. T99wt is a naturally occurring human antibody light chain that we transformed into its catalytic antibody using Pro95 deletion. In peptidase activity tests, T99wt exhibited a low catalytic activity against a synthetic peptide Arg-pNA and hardly cleaved amyloid-β peptide. In contrast, the engineered variant (T99-Pro95(-)) demonstrated significant catalytic activity, effectively cleaving both Arg-pNA substrate and amyloid-β peptides. In this study, the structural basis for the acquisition of enzymatic function through Pro95 deletion in the CDR-3 region of the light chain was elucidated using X-ray crystallography and molecular dynamics (MD) simulations. X-ray crystallography revealed that Pro95 deletion substantially reduces the distance between Asp1 and His93-key residues for catalytic activity - from 9.56 Å in T99wt to 3.84 Å in T99-Pro95(-). The observed decrease in distance indicates a strong interaction between Asp1(Oδ1) and His93(Nε2), contributing to the formation of an active site in T99-Pro95(-). MD simulations revealed that the entire structure exhibits slight fluctuations and adopts various configurations upon the removal of Pro95. In particular, when His residues in the catalytic region are fully deprotonated, Asp1, His93, and Ser27a transiently come into close proximity, enabling the formation of a functional catalytic triad. Catalytic antibodies can be made starting from just the amino acid sequence of a desired mAb, which may be available in databases such as OAS or IMGT. Therefore, our finding represents a significant technological advancement.

非催化型和催化型抗体的结构和生化差异。
如前所述,常规抗体可以通过删除人和小鼠抗体轻链CDR-3中的Pro95转化为其催化对偶物。T99wt是一种天然存在的人抗体轻链,我们使用Pro95缺失将其转化为催化抗体。在肽酶活性测试中,T99wt对合成肽Arg-pNA和难裂解淀粉样蛋白-β肽表现出较低的催化活性。相比之下,工程变体(T99-Pro95(-))表现出显著的催化活性,可以有效地切割Arg-pNA底物和淀粉样蛋白-β肽。在这项研究中,通过x射线晶体学和分子动力学(MD)模拟阐明了通过在轻链CDR-3区域缺失Pro95获得酶功能的结构基础。x射线晶体学显示,Pro95缺失大大缩短了催化活性的Asp1和his93关键残基之间的距离-从T99wt的9.56 Å到T99-Pro95(-)的3.84 Å。观察到的距离减小表明Asp1(Oδ1)和His93(Nε2)之间存在强烈的相互作用,有助于在T99-Pro95(-)中形成一个活性位点。MD模拟结果表明,去除Pro95后,整个结构出现了轻微的波动,并呈现出多种构型。特别是,当催化区域的His残基完全去质子化时,Asp1、His93和Ser27a会瞬间靠近,从而形成功能性催化三联体。催化抗体可以从所需单抗的氨基酸序列开始制备,这可能在OAS或IMGT等数据库中可用。因此,我们的发现代表了一项重大的技术进步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
mAbs
mAbs 工程技术-仪器仪表
CiteScore
10.70
自引率
11.30%
发文量
77
审稿时长
6-12 weeks
期刊介绍: mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信